Value Line, Inc. Announces Third Quarter Earnings NEW

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
151
Value Line, Inc. Announces Third Quarter Earnings

NEW YORK, March 13, 2017 (GLOBE NEWSWIRE) -- Value Line, Inc., (NASDAQ: VALU ) reported results for the third fiscal quarter ended January 31, 2017. 

During the nine months ended January 31, 2017, the Company’s net income of $9,283,000, or $0.96 per share, was $3,259,000 or 54.1% above net income of $6,024,000, or $0.62 per share, for the nine months ended January 31, 2016.  Income from operations of $7,948,000 for the nine months ended January 31, 2017 which included additional depreciation and amortization expense of $1,526,000 was $5,606,000 above income from operations of $2,342,000 for the nine months ended January 31, 2016. Loss from operations of $212,000 for the three months ended January 31, 2017 was $769,000 below income from operations of $557,000 for the three months ended January 31, 2016 primarily as a result of a decrease in the capitalization of internal salaries and benefits expenses for digital project development of $300,000 and an additional depreciation and amortization expense of $208,000 during the third quarter of fiscal 2017.  During the three months ended January 31, 2017, the Company’s net income of $1,445,000, or $0.15 per share, was $468,000 or 24.5% below net income of $1,913,000, or $0.20 per share, for the three months ended January 31, 2016.  During the first nine months of fiscal 2017 both net income and income from operations included a pre-tax gain of $8,123,000 from the sale of the Company's operating facility for which it received proceeds of $11,555,000 on July 29, 2016.  The fulfillment and mailing operations housed within the facility were relocated to a nearby area of New Jersey. Value Line’s New York City corporate office successfully relocated to a new leased facility located at 551 Fifth Avenue, New York, NY.

Shareholders’ equity of $38,395,000 at January 31, 2017 increased $3,795,000 compared to shareholders’ equity of $34,600,000 at April 30, 2016.  As of January 31, 2017, retained earnings and liquid assets were $39,850,000 and $21,473,000, respectively.  During the nine months ended January 31, 2017 there were 9,724,377 average common shares outstanding as compared to 9,787,208 average common shares outstanding during the nine months ended January 31, 2016.

The Company’s quarterly report on Form 10-Q has been filed with the SEC and is available on the Company’s website at www.valueline.com/About/corporate_filings.aspx .  Shareholders may receive a printed copy, free of charge upon request.

Value Line, Inc. is a leading New York based provider of investment research. The Value Line Investment Survey is one of the most widely used sources of independent equity investment research.  Value Line also publishes a range of proprietary investment research in both print and digital formats including research in the areas of Mutual Funds, Options and Convertible securities.  Value Line’s acclaimed research also enables the Company to provide specialized products such as Value Line Select, Value Line Special Situations, Value Line Select: Dividend Income & Growth, and copyright data , distributed under copyright agreements for fees, including certain proprietary ranking system information and other proprietary information used in third party products.  Investment Management services are provided through its substantial non-controlling and non-voting interests in EULAV Asset Management, the investment advisor to The Value Line Family of Mutual Funds. Value Line’s products are available to individual investors by mail, at www.valueline.com or through 1-800-VALUELINE or 1-800-535-9648, while institutional-level services for professional investors, advisers, corporate, academic, municipal and legal libraries are offered at www.ValueLinePro.com , www.ValueLineLibrary.com and at 1-800-531-1425. 

Cautionary Statement Regarding Forward-Looking Information

This report contains statements that are predictive in nature, depend upon or refer to future events or conditions (including certain projections and business trends) accompanied by such phrases as “believe”, “estimate”, “expect”, “anticipate”, “will”, “intend” and other similar or negative expressions, that are “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995, as amended.  Actual results for Value Line, Inc. (“Value Line” or “the Company”) may differ materially from those projected as a result of certain risks and uncertainties, including but not limited to the following:

  • maintaining revenue from subscriptions for the Company’s digital and print published products;
  • changes in market and economic conditions, including global financial issues;
  • protection of intellectual property rights;
  • dependence on non-voting revenues and non-voting profits interests in EULAV Asset Management, a Delaware statutory trust (“EAM” or “EAM Trust”), which serves as the investment advisor to the Value Line Funds and engages in related distribution, marketing and administrative services;
  • fluctuations in EAM’s assets under management due to broadly based changes in the values of equity and debt securities, redemptions by investors and other factors, and the effect these changes may have on the valuation of EAM’s intangible assets;
  • dependence on key personnel;
  • competition in the fields of publishing, copyright data and investment management;
  • the impact of government regulation on the Company’s and EAM’s businesses;
  • availability of free or low cost investment data through discount brokers or generally over the internet;
  • terrorist attacks, cyber attacks and natural disasters;
  • other risks and uncertainties, including but not limited to the risks described in Item 1A, “Risk Factors” of the Company’s Annual Report on Form 10-K for the year ended April 30, 2016; and in Part II, Item 1A of the Quarterly Report on Form 10-Q for the period ended January 31, 2017; and
  • other risks and uncertainties arising from time to time.

These factors are not necessarily all of the important factors that could cause actual results to differ materially from those expressed in any of our forward-looking statements. Other unknown or unpredictable factors which may involve external factors over which we may have no control or changes in our plans, strategies, objectives, expectations or intentions, which may happen at any time at our discretion, could also have material adverse effects on future results. Except as otherwise required to be disclosed in periodic reports required to be filed by public companies with the SEC pursuant to the SEC's rules, we have no duty to update these statements, and we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. In light of these risks and uncertainties, current plans, anticipated actions, and future financial conditions and results may differ from those expressed in any forward-looking information contained herein.

Contact: Howard A. Brecher                                                                                                             Value Line, Inc. (212) 907-1500                                                                                    www.valueline.com www.ValueLinePro.com , www.ValueLineLibrary.com Facebook | Google+ | LinkedIn | Twitter Complimentary Value Line® Reports on Dow 30 Stocks

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Innovent's SINTBILO® Hits Primary Endpoint in Study

Updated Category News Views 119

Innovent's Latest Breakthrough with SINTBILO® One moment you're sipping coffee, the next you're staring at a clinical milestone. Innovent Biologics has shouted from the rooftops that their drug, SINTBILO® (tafolecimab injection), has wrapped up its Phase 3 CREDIT-5 study, snagging the primary endpoint with both hands. This isn't just any drug; it's marked as the first...

Continue Reading
Stavian Group Eyes AI-Driven Southeast Asia Growth

Updated Category News Views 50

AI and Infrastructure: A New Chapter for Southeast Asia What does Southeast Asia's future look like with AI steering the ship? Well, there's a fresh breeze of change blowing, and right at the heart of it stands Stavian Group. At the recently held inaugural Fortune SEA500 Summit in Ho Chi Minh City, this conglomerate threw its hat into the ring, painting a vision of growth...

Continue Reading
Intelligent Communication Forum Eyes Global Ecosystem Shift

Updated Category News Views 612

China's Grand Vision for Intelligent Communication You know what they say about big ideas—they start in the most bustling of places. And here we are in Wuxi, a city's pulse pounding with ambition, hosting the 2026 China International Intelligent Communication Forum. Picture it: From November 8th to 10th, movers, shakers, and visionaries are scribbling new blueprints for...

Continue Reading
Antengene’s AnTenGager-D2 Advances in Cancer Treatment

Updated Category News Views 56

Antengene's AnTenGager-D2 Offers Fresh Hope Alright, let's dig into the latest buzz from the 2026 Society for Immunotherapy of Cancer conference about Antengene's AnTenGager-D2 platform. If you're not into biotech lingo, buckle up, because this is a ride into the future of cancer treatments—where science fiction might soon become science fact. A Novel Approach to Tumor...

Continue Reading
D-Wave's Legal Trouble: Securities Fraud Suit Looms

Updated Category News Views 351

A Looming Legal Storm for D-Wave Investors Call it another day, another legal tangle in the investing world. This time, it's D-Wave Quantum Inc. (NASDAQ: QBTS) on the receiving end of a securities fraud class action lawsuit. Yeah, those fancy quantum computers they're pushing didn't predict this one coming. The legal arena is getting ready for a bout, and if you've got...

Continue Reading
CureGene's Evategrel Aims for Breakthrough in Stroke Care

Updated Category News Views 69

Revolutionizing Stroke Care: Enter Evategrel When it comes to strokes, time is money—and I'm telling you, this ain't an area where you can afford to twiddle your thumbs. The faster you can get that blood flowing again, the better the chance you've got of walking away with less damage. That's where CureGene's new investigational drug, Evategrel, comes in. Why Evategrel...

Continue Reading
Allergan Aesthetics Study Shows Rising Patient Satisfaction

Updated Category News Views 344

Enhanced Patient Satisfaction with Aesthetic Treatments Dive into the latest studies from Allergan Aesthetics—AbbVie's heavyweight in the beauty battleground. If you've got an ounce of optimism left in this market, their recent findings might just lift your spirits. Phase 4 studies, namely HARMONY IN DIVERSITY and HALO, are showing highly positive results among patients...

Continue Reading
Gildan's Crisis: Investors Face Losses Amid Lawsuit

Updated Category News Views 245

Gildan Investors, Brace Yourself Poor old Gildan Activewear finds itself in hot water again, with a class action lawsuit cropping up like an unexpected storm on farmers' day. Any traders remotely involved with NYSE:GIL should pay damn close attention, because with a December 14, 2026 deadline looming, it's crunch time. The Root of the Lawsuit The plot thickens here,...

Continue Reading
JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer

Updated Category News Views 273

Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...

Continue Reading
GlycoNex Eyes Japanese Market with Denosumab Biosimilar

Updated Category News Views 84

A Strategic Step into the Japanese Market Alright folks, there's a new kid aiming to shake things up in the biotech neighborhood, and it's GlycoNex with its denosumab biosimilar, SPD8. These guys just tossed their hat in the ring with a regulatory submission to Japan's Pharmaceuticals and Medical Devices Agency (PMDA). If the cosmic forces align, they might snag an...

Continue Reading

Top 5 Most Recently Viewed Articles

Equitage Ventures Launches $47.3M Fund for Senior Care Tech

Updated Category News Views 329

Equitage Ventures Launches Significant Investment Fund Equitage Ventures, an early-stage venture capital firm dedicated to AgeTech, has announced the successful final closing of a substantial $47.3 million investment fund. This fund is designed to provide critical capital, distribution resources, and strategic guidance to innovative entrepreneurs who aim to tackle the...

Continue Reading
Understanding Market Trends: Insights into Chevron Corp's Performance

Updated Category News Views 171

Chevron Corp Market Sentiment Analysis Chevron Corp (NYSE: CVX) has experienced a noteworthy decline in its short interest as a percentage of float, showing a 10.26% decrease since its previous report. Currently, there are approximately 14.02 million shares sold short, which accounts for 0.7% of all shares available for trading. Given the trading volume, it is estimated...

Continue Reading
Establishment of Blakely McCrory Hope Fund at Moody Gardens

Updated Category News Views 200

Introducing the Blakely McCrory Hope Fund Moody Gardens is proud to announce a special initiative to honor the memory of a young girl who captured the hearts of many: the Blakely McCrory Hope Fund. This fund has been established in loving memory of 8-year-old Blakely McCrory, who lost her life in a tragic flooding incident that occurred during the summer months....

Continue Reading
Star-Studded Table Read of 'It's a Wonderful Life' Event

Updated Category News Views 221

Exciting Holiday Table Read for a Worthy Cause The Ed Asner Family Center is pulling out all the stops this holiday season with an exciting virtual table read of the beloved classic, "It's a Wonderful Life." Scheduled for December 14 at 5 PM PST, this event promises to spread joy while supporting individuals and families with special needs. Star-Studded Cast Comes...

Continue Reading
Transforming $100 Into Over $1700 with Monolithic Power Systems

Updated Category News Views 145

Understanding the Growth of Monolithic Power Systems Monolithic Power Systems (NASDAQ: MPWR) has showcased impressive financial performance over the past decade, outperforming many market benchmarks. With an impressive annualized growth rate of 19.88%, it has attracted the attention of savvy investors. The Power of Compounded Returns Imagine investing $100 in MPWR stock...

Continue Reading